ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Indole-benzimidazole hybrids modulate lipid metabolism and promote autophagic and apoptotic signaling in breast cancer.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid metabolic reprogramming is a hallmark of breast cancer, enabling tumor cells to sustain proliferation, adapt to metabolic stress, and develop therapeutic resistance. Consequently, targeting lipid metabolism has emerged as a promising pharmacological strategy for cancer treatment. In the present study, we investigated the anticancer effects of two novel indole-benzimidazole hybrid compounds, IBB-6 and IBB-7, in MCF-7 and MDA-MB-231 breast cancer cells, with a particular focus on lipid droplet homeostasis and its associated regulatory pathways. Both compounds exhibited significant dose-dependent cytotoxic activity and markedly reduced lipid droplet accumulation, particularly in MCF-7 cells. Molecular analyses revealed that treatment with IBB-6 and IBB-7 suppressed the expression of key lipogenic regulators, including fatty acid synthase (FASN), SREBP cleavage-activating protein (SCAP), MLXIPL (also known as ChREBP), and sphingosine-1-phosphate receptor 1 (S1P1), indicating a disruption of lipid biosynthesis and metabolic adaptation. In parallel, the compounds modulated autophagy-related pathways, as evidenced by increased expression of LC3, ATG6, and HIF-1α, suggesting activation of cellular stress responses associated with metabolic perturbation. Furthermore, both derivatives promoted a pro-apoptotic transcriptional profile characterized by increased Bax and Caspase-7 expression and reduced Bcl-2 levels, supporting the induction of apoptotic cell death. Collectively, these findings demonstrate that indole-benzimidazole hybrids function as multifunctional modulators of breast cancer cell metabolism by coordinately targeting lipid homeostasis, sphingolipid-associated signaling, autophagic regulation, and apoptosis. The ability of IBB-6 and IBB-7 to impair metabolic adaptability and promote cancer cell death highlights their potential as promising therapeutic candidates for breast cancer treatment and warrants further mechanistic and in vivo investigations.
Indexed as
Identifiers
42722901What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.